Nathan Haas - Nov 11, 2022 Form 3 Insider Report for Vitro Biopharma, Inc. (NONE)

Role
Chief Financial Officer
Signature
/s/ Nathan Haas
Stock symbol
NONE
Transactions as of
Nov 11, 2022
Transactions value $
$0
Form type
3
Date filed
11/14/2022, 01:33 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NONE Common Stock 1.88M Nov 11, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NONE Employee Stock Option (Right to Buy) Nov 11, 2022 Common Stock 1M $0.50 Direct F1
holding NONE Employee Stock Option (Right to Buy) Nov 11, 2022 Common Stock 500K $0.50 Direct F2
holding NONE Warrant (Right to Buy) Nov 11, 2022 Common Stock 120K $0.50 Direct
holding NONE Warrant (Right to Buy) Nov 11, 2022 Common Stock 120K $1.00 Direct
holding NONE Warrant (Right to Buy) Nov 11, 2022 Common Stock 400K $0.50 Direct
holding NONE Warrant (Right to Buy) Nov 11, 2022 Common Stock 400K $1.00 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option became exercisable as to 200,000 shares on August 1, 2022, and will become exercisable as to (i) 200,000 shares on August 1, 2023, (ii) 200,000 shares on August 1, 2024, (iii) 200,000 shares on August 1, 2025, and (iv) 200,000 shares on August 1, 2026.
F2 The option became exercisable as to 100,000 shares on October 1, 2022, and will become exercisable as to (i) 100,000 shares on October 1, 2023, (ii) 100,000 shares on October 1, 2024, (iii) 100,000 shares on October 1, 2025, and (iv) 100,000 shares on October 1, 2026.